TRANSTHERA-B (02617) has entered into a placement agreement with a placement agent. The agreement, dated April 14, 2026, stipulates that the agent will use its best efforts to place 5.085 million shares with subscribers at a price of HK$57.03 per share. Assuming no change in the number of issued shares between the announcement date and the settlement date, the 5.085 million placement shares represent approximately 1.67% of the existing issued H-shares and 1.27% of the total issued shares as of the announcement date. Following the completion of the placement, these shares will account for about 1.65% of the enlarged issued H-share capital and approximately 1.26% of the total enlarged share capital. The placement price of HK$57.03 per share represents a discount of approximately 18.00% compared to the closing price of HK$69.55 per H-share on the Hong Kong Stock Exchange on April 14, 2026, the last trading day. Assuming all placement shares are successfully subscribed for, the gross proceeds from the placement are expected to be approximately HK$290 million, with estimated net proceeds of around HK$282 million after deducting commissions and other related expenses. The company intends to allocate the net proceeds as follows: approximately 57% will be used for research and development, including the clinical development of its core product Tinengotinib for indications such as advanced breast cancer, hepatocellular carcinoma, and castration-resistant prostate cancer, as well as the clinical development of TT-00973; approximately 33% will be allocated to the production and commercialization of its core product Tinengotinib in China, covering the establishment of a commercial team and related marketing activities; and the remaining 10% will be reserved for working capital and general corporate purposes.